Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV
Identifieur interne : 005F80 ( Main/Merge ); précédent : 005F79; suivant : 005F81Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV
Auteurs : Miriam E. R. Darnell [États-Unis] ; Kanta Subbarao [États-Unis] ; Stephen M. Feinstone [États-Unis] ; Deborah R. Taylor [États-Unis]Source :
- Journal of virological methods [ 0166-0934 ] ; 2004.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a novel coronavirus termed SARS-CoV. Due to the severity of this disease, the World Health Organization (WHO) recommends that manipulation of active viral cultures of SARS-CoV be performed in containment laboratories at biosafety level 3 (BSL3). The virus was inactivated by ultraviolet light (UV) at 254 nm, heat treatment of 65 °C or greater, alkaline (pH > 12) or acidic (pH < 3) conditions, formalin and glutaraldehyde treatments. We describe the kinetics of these efficient viral inactivation methods, which will allow research with SARS-CoV containing materials, that are rendered non-infectious, to be conducted at reduced safety levels.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000794
- to stream PascalFrancis, to step Curation: 000196
- to stream PascalFrancis, to step Checkpoint: 000829
Links to Exploration step
Pascal:04-0535983Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV</title>
<author><name sortKey="Darnell, Miriam E R" sort="Darnell, Miriam E R" uniqKey="Darnell M" first="Miriam E. R." last="Darnell">Miriam E. R. Darnell</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Feinstone, Stephen M" sort="Feinstone, Stephen M" uniqKey="Feinstone S" first="Stephen M." last="Feinstone">Stephen M. Feinstone</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Deborah R" sort="Taylor, Deborah R" uniqKey="Taylor D" first="Deborah R." last="Taylor">Deborah R. Taylor</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0535983</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0535983 INIST</idno>
<idno type="RBID">Pascal:04-0535983</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000794</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000196</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000829</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000829</idno>
<idno type="wicri:doubleKey">0166-0934:2004:Darnell M:inactivation:of:the</idno>
<idno type="wicri:Area/Main/Merge">005F80</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV</title>
<author><name sortKey="Darnell, Miriam E R" sort="Darnell, Miriam E R" uniqKey="Darnell M" first="Miriam E. R." last="Darnell">Miriam E. R. Darnell</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Feinstone, Stephen M" sort="Feinstone, Stephen M" uniqKey="Feinstone S" first="Stephen M." last="Feinstone">Stephen M. Feinstone</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Deborah R" sort="Taylor, Deborah R" uniqKey="Taylor D" first="Deborah R." last="Taylor">Deborah R. Taylor</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of virological methods</title>
<title level="j" type="abbreviated">J. virol. methods</title>
<idno type="ISSN">0166-0934</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of virological methods</title>
<title level="j" type="abbreviated">J. virol. methods</title>
<idno type="ISSN">0166-0934</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus</term>
<term>Method</term>
<term>Microbiology</term>
<term>Severe acute respiratory syndrome</term>
<term>Tissue culture</term>
<term>Virology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term>
<term>Culture tissu</term>
<term>Microbiologie</term>
<term>Méthode</term>
<term>Virologie</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a novel coronavirus termed SARS-CoV. Due to the severity of this disease, the World Health Organization (WHO) recommends that manipulation of active viral cultures of SARS-CoV be performed in containment laboratories at biosafety level 3 (BSL3). The virus was inactivated by ultraviolet light (UV) at 254 nm, heat treatment of 65 °C or greater, alkaline (pH > 12) or acidic (pH < 3) conditions, formalin and glutaraldehyde treatments. We describe the kinetics of these efficient viral inactivation methods, which will allow research with SARS-CoV containing materials, that are rendered non-infectious, to be conducted at reduced safety levels.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Darnell, Miriam E R" sort="Darnell, Miriam E R" uniqKey="Darnell M" first="Miriam E. R." last="Darnell">Miriam E. R. Darnell</name>
</region>
<name sortKey="Feinstone, Stephen M" sort="Feinstone, Stephen M" uniqKey="Feinstone S" first="Stephen M." last="Feinstone">Stephen M. Feinstone</name>
<name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<name sortKey="Taylor, Deborah R" sort="Taylor, Deborah R" uniqKey="Taylor D" first="Deborah R." last="Taylor">Deborah R. Taylor</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005F80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005F80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Merge |type= RBID |clé= Pascal:04-0535983 |texte= Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |